Cardiovascular adverse events associated with oral antineoplastic therapy.
Rev Bras Enferm 2018;
71:2561-2569. [PMID:
30304190 DOI:
10.1590/0034-7167-2017-0450]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2017] [Accepted: 10/18/2017] [Indexed: 12/16/2022] Open
Abstract
OBJECTIVE
To identify in the literature the cardiovascular adverse events resulting from oral antineoplastic therapy.
METHOD
Integrative review of the literature through the SCOPUS, Scientific Electronic Library Online (SciELO), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Medical Literature Analysis and Retrieval System Online (MEDLINE) databases. The antineoplastic, cardiotoxicity, cardiovascular system and adverse reaction descriptors were used in Portuguese, English and Spanish. We selected 23 articles published between 1985 and 2015.
RESULTS
Twenty studies were related to cardiac events and eleven to peripheral vascular events. The most frequent adverse cardiac events were reduced left ventricular ejection fraction, myocardial infarction, changes in the electrocardiogram, heart failure and angina, whereas peripheral vascular events were hypertension and thromboembolism.
CONCLUSION
Oral antineoplastic therapy is associated with different adverse events, including cardiac and peripheral vascular events.
Collapse